The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy
- PMID: 20103708
- PMCID: PMC2844833
- DOI: 10.2337/db09-1342
The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy
Abstract
Objective: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS). Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis. Here, we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy.
Research design and methods: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.
Results: The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels. In the animal study, Nrf2 was demonstrated to be crucial in ameliorating streptozotocin-induced renal damage. This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice. Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production. In human renal mesangial cells, high glucose induced ROS production and activated expression of Nrf2 and its downstream genes. Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-beta1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-beta1 transcription and fibronectin production.
Conclusions: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.
Figures
Similar articles
-
Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy.Diabetes. 2011 Nov;60(11):3055-66. doi: 10.2337/db11-0807. Diabetes. 2011. PMID: 22025779 Free PMC article.
-
Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-β1 by activating the Nrf2/ARE pathway in glomerular mesangial cells.Free Radic Biol Med. 2013 Dec;65:528-540. doi: 10.1016/j.freeradbiomed.2013.07.029. Epub 2013 Jul 24. Free Radic Biol Med. 2013. PMID: 23891678
-
Potential role for Nrf2 activation in the therapeutic effect of MG132 on diabetic nephropathy in OVE26 diabetic mice.Am J Physiol Endocrinol Metab. 2013 Jan 1;304(1):E87-99. doi: 10.1152/ajpendo.00430.2012. Epub 2012 Nov 6. Am J Physiol Endocrinol Metab. 2013. PMID: 23132297
-
Sestrin2 Signaling Pathway Regulates Podocyte Biology and Protects against Diabetic Nephropathy.J Diabetes Res. 2023 Feb 10;2023:8776878. doi: 10.1155/2023/8776878. eCollection 2023. J Diabetes Res. 2023. PMID: 36818747 Free PMC article. Review.
-
Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy.Exp Diabetes Res. 2012;2012:216512. doi: 10.1155/2012/216512. Epub 2012 May 8. Exp Diabetes Res. 2012. PMID: 22645602 Free PMC article. Review.
Cited by
-
USP15 negatively regulates Nrf2 through deubiquitination of Keap1.Mol Cell. 2013 Jul 11;51(1):68-79. doi: 10.1016/j.molcel.2013.04.022. Epub 2013 May 30. Mol Cell. 2013. PMID: 23727018 Free PMC article.
-
Hepatic AMPK signaling dynamic activation in response to REDOX balance are sentinel biomarkers of exercise and antioxidant intervention to improve blood glucose control.Elife. 2022 Sep 26;11:e79939. doi: 10.7554/eLife.79939. Elife. 2022. PMID: 36155132 Free PMC article.
-
Quercetin-conjugated superparamagnetic iron oxide nanoparticles (QCSPIONs) increases Nrf2 expression via miR-27a mediation to prevent memory dysfunction in diabetic rats.Sci Rep. 2020 Sep 29;10(1):15957. doi: 10.1038/s41598-020-71971-2. Sci Rep. 2020. PMID: 32994439 Free PMC article.
-
Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents.Med Res Rev. 2012 Jul;32(4):687-726. doi: 10.1002/med.21257. Epub 2012 May 1. Med Res Rev. 2012. PMID: 22549716 Free PMC article. Review.
-
Ferroptosis as a Novel Determinant of β-Cell Death in Diabetic Conditions.Oxid Med Cell Longev. 2022 Mar 14;2022:3873420. doi: 10.1155/2022/3873420. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35320979 Free PMC article.
References
-
- Ismail N, Becker B, Strzelczyk P, Ritz E: Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999; 55: 1– 28 - PubMed
-
- Cooper ME: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213– 219 - PubMed
-
- Zheng F, Guan Y: Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy? Kidney Int 2007; 72: 1301– 1303 - PubMed
-
- Debnam ES, Unwin RJ: Hyperglycemia and intestinal and renal glucose transport: implications for diabetic renal injury. Kidney Int 1996; 50: 1101– 1109 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
